{"entity":{"id":"nct07174583","kind":"trial","name":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of Durvalumab, Carboplatin in small-cell lung cancer, run by IDEAYA Biosciences, now recruiting.","summary":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07174583 by IDEAYA Biosciences, with 262 participants planned, started 2025-10-14 and due to reach its primary completion in 2029-07. Interventions recorded: IDE849, durvalumab, IDE161, Carboplatin. Conditions listed: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07174583","url":"https://clinicaltrials.gov/study/NCT07174583"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","carboplatin"],"companies":["ideaya-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07174583","phase":"1/2","setting":"A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer","sponsor":"IDEAYA Biosciences","enrolled":262,"outcomes":[]},"route":"/trials/nct07174583/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"ideaya-biosciences","kind":"company","name":"IDEAYA Biosciences","route":"/companies/ideaya-biosciences/"}]}}